BLCO
Bausch + Lomb Corp.

521
Mkt Cap
$6.05B
Volume
15,405.00
52W High
$18.14
52W Low
$10.45
PE Ratio
-19.78
BLCO Fundamentals
Price
$17.34
Prev Close
$17.09
Open
$17.30
50D MA
$16.57
Beta
1.11
Avg. Volume
346,552.82
EPS (Annual)
-$0.9011
P/B
0.94
Rev/Employee
$354,888.89
Loading...
Loading...
News
all
press releases
Bausch + Lomb Will Release Fourth-Quarter and Full-Year 2025 Financial Results on Feb. 18
Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its fourth-quarter and full-year 2025 financial...
Business Wire·1d ago
News Placeholder
More News
News Placeholder
Bausch + Lomb Corporation (NYSE:BLCO) Receives Consensus Recommendation of "Hold" from Analysts
Shares of Bausch + Lomb Corporation (NYSE:BLCO - Get Free Report) have been given a consensus recommendation of "Hold" by the fifteen brokerages that are presently covering the company...
MarketBeat·6d ago
News Placeholder
Bausch + Lomb Partners with Glaucoma Research Foundation and The Glaucoma Foundation to Address a Leading Cause of Irreversible Blindness in the U.S.
Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, is launching its fifth annual fundraising challenge with...
Business Wire·16d ago
News Placeholder
Bausch + Lomb Completes Refinancing of Outstanding Term B Loans
Bausch + Lomb Corporation (NYSE/TSX: BLCO) (Bausch + Lomb or the company), a leading global eye health company dedicated to helping people see better to live better, today announced that it closed...
Business Wire·19d ago
News Placeholder
Bausch + Lomb to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Chairman and CEO Brent Saunders, Executive...
Business Wire·29d ago
News Placeholder
Bausch + Lomb Corporation (NYSE:BLCO) Given Average Recommendation of "Hold" by Brokerages
Bausch + Lomb Corporation (NYSE:BLCO - Get Free Report) has been given a consensus recommendation of "Hold" by the fifteen brokerages that are presently covering the stock, MarketBeat reports. Two...
MarketBeat·1mo ago
News Placeholder
Bausch + Lomb Announces Two Board of Directors Appointments
Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Eduardo C. Alfonso, MD, and Steven H...
Business Wire·1mo ago
News Placeholder
Fund Exits $6.6 Million Bausch + Lomb Stake as Shares Lag by 9% This Past Year
Key PointsNew York City-based DSC Meridian Capital sold 510,090 shares in Bausch + Lomb during the third quarter...
Nasdaq News: Markets·1mo ago
News Placeholder
Nomura Holdings Inc. Cuts Holdings in Bausch + Lomb Corporation $BLCO
Nomura Holdings Inc. lowered its stake in shares of Bausch + Lomb Corporation (NYSE:BLCO - Free Report) by 7.4% during the 2nd quarter, according to the company in its most recent 13F filing with the...
MarketBeat·1mo ago
News Placeholder
Bausch + Lomb Announces Refinancing of Outstanding Term B Loans
Bausch + Lomb Corporation (NYSE/TSX: BLCO) (Bausch + Lomb or the company), a leading global eye health company dedicated to helping people see better to live better, today announced that it allocated...
Business Wire·1mo ago
<
1
2
...
>

Latest BLCO News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.